Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Psychopharmacology (Berl). 2016 Apr 13;233(12):2399–2410. doi: 10.1007/s00213-016-4291-0

Table 1.

PBO MCCB performance (post-placebo)

PBO MCCB domain T-score All subjects
Main analysis with diagnosis as between-subject factor
 Diagnosis (Dx) F = 38.71, df (1,78), p < 0.0001
 Domain F = 10.72, df (6, 468), p < 0.0001
 Domain × Dx F = 4.13, df (6, 468), p = 0.0005
Additional analyses with either sex/age/test order/dose as between-subject factor
 1. Gender F < 1
 2. Age (median split) F = 6.35, df (1,78), p = 0.01
  Age × domain F = 2.83, df (6, 468), p = 0.01
  Age × Dx F < 1
  Age × domain × Dx F < 1
 3. Test order F = 4.94, df (1,78), p < 0.03
  Test order × domain F = 2.46, df (6, 468), p < 0.025
  Test order × Dx F < 1
 4. Dose F < 1
  Dose × Dx F = 5.23, df (1,78), p < 0.025
  Dose × domain NS
  Dose × domain × Dx NS
In CPD subjects only
 5. Smoking status (SS) F < 1
  Domain × SS F = 3.82, df (6, 234), p < 0.002
PBO composite T-score CPD subjects
Anticholinergic activity (low vs. high, split >15/≤ 15) F = 8.71, df (1,35), p = 0.005
Correlation(s) vs. PBO composite T-score
 Global assessment of function score R = 0.5, p = 0.001
 Duration of illness (years) R = 0.04, NS